2023年年在审查中:早期乳腺癌
Guilherme Nader-Marta1, Ann H Partridge1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast (Edinburgh, Scotland)
|February 29, 2024
概括
在2023年,研究表明,针对早期乳腺癌的量身定制治疗可以安全地省略为特定患者的淋巴结剖析和放射治疗. 免疫疗法和CDK4/6抑制剂对特定的高风险乳腺癌类型提供了好处.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 临床试验 临床试验
背景情况:
- 个性化医疗正在彻底改变早期乳腺癌治疗.
- 识别高风险患者对于优化治疗策略至关重要.
- 免疫疗法和向疗法的进步正在改变治疗模式.
研究的目的:
- 评估在精选早期乳腺癌患者中省略下淋巴结解剖和放射治疗的安全性和有效性.
- 评估助剂CDK4/6抑制剂对高风险激素受体阳性乳腺癌的持续益处.
- 确定免疫疗法 (pembrolizumab和atezolizumab) 对三阴性乳腺癌病理反应和复发风险的影响.
主要方法:
- 从2023年开始分析临床试验数据,重点关注量身定制的治疗方法.
- 对接受或不接受特定干预的患者的结果的回顾性和前性评估.
- 评估不同乳腺癌亚型的病理反应率和无复发生存率.
主要成果:
- 选择的早期乳腺癌患者可以安全地避免下淋巴结剖析和放射治疗.
- 高风险的激素受体阳性乳腺癌显示,辅助性CDK4/6抑制剂的持续益处.
- 术后 pembrolizumab 改善了三阴性乳腺癌的结果; atezolizumab 并没有显著降低复发风险.
- 年轻的患者在治疗后怀孕的可能性更高.
结论:
- 量身定制的治疗策略,包括放弃某些程序和使用向疗法/免疫疗法,对于特定的早期乳腺癌患者群体是有效的.
- CDK4/6抑制剂和潘布罗利祖马布在高风险和三阴性乳腺癌中分别显示出显著的益处.
- 需要进一步的研究来优化免疫治疗的使用,并了解乳腺癌幸存者的长期结果,包括生育能力.
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:30Cancer Vaccines
367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367